Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carnival Corp (CCL) vs Nuvalent Inc (NUVL) Price & Performance

Carnival CorpTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Carnival Corp vs Nuvalent Inc — how do they compare? Carnival Corp trades at $26.62 (market cap $36.30B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Carnival Corp is far larger — about 3.7× Nuvalent Inc's market cap, and Carnival Corp pays a 1.7% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

CCLNUVL
Market Cap
$36.30B$9.81B
Sector
Consumer CyclicalTechnology
52-Week High
$33.99$123.96
52-Week Low
$23.89$72.16
Enterprise Value
$60.22B$8.52B
Dividend Yield
1.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carnival Corp

Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.

The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.

Nuvalent Inc

Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.

The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carnival Corp

Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.

Read more on CCL

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL